BioNTech, the company that helped develop Pfizer’s coronavirus vaccine, says there’s “no evidence” they need to adjust the vaccine to be more effective against Covid-19 variants.
The World Health Organization and Centers For Disease Control have expressed their concerns about Covid-19 variants that have hit Europe , Africa and India.
But BioNTech and Pfizer on planning on studying what impact a third vaccine or booster vaccine would have in protecting people against the variants of the virus.
The FDA has already approved the research plans.
FILE – In this Saturday, Feb. 13, 2021 file photo the logo on the BioNTech biotechnology company displayed at the building where production of the COVID-19 vaccine has started, in Marburg, Germany. German pharmaceutical company BioNTech reported a net profit of 1.13 billion euros, about 1.37 billion US dollars, in the first quarter of this year on the back of strong revenues from its coronavirus vaccine. (AP Photo/Michael Probst, file) May 10th 2021